[{"id":"24101395-efd5-45f7-b263-ca1e7f90853b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02915445","created_at":"2021-01-18T14:18:46.620Z","updated_at":"2024-07-02T16:35:28.369Z","phase":"Phase 1","brief_title":"EpCAM CAR-T for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT02915445","lead_sponsor":"Sichuan University","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-22"},{"id":"e6fa6f5f-f47f-4e45-ac2a-8106517e9c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT04021394","created_at":"2021-01-18T19:44:45.886Z","updated_at":"2024-07-02T16:35:51.538Z","phase":"","brief_title":"Influence of EMT on CTCs and Disease Progression in Prostate Cancer","source_id_and_acronym":"NCT04021394","lead_sponsor":"Lawson Health Research Institute","biomarkers":" CDH1 • EPCAM • CDH2 • ZEB1","pipe":" | ","alterations":" AR expression • CDH1 expression • EPCAM expression • ZEB1 expression","tags":["CDH1 • EPCAM • CDH2 • ZEB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • CDH1 expression • EPCAM expression • ZEB1 expression"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 04/27/2021","primary_completion_date":" 04/27/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-04-04"},{"id":"42ddb378-1446-4084-a290-35601a846939","acronym":"","url":"https://clinicaltrials.gov/study/NCT05703815","created_at":"2023-01-30T18:59:49.220Z","updated_at":"2024-07-02T16:35:56.697Z","phase":"","brief_title":"EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast","source_id_and_acronym":"NCT05703815","lead_sponsor":"Sohag University","biomarkers":" TP53 • EPCAM","pipe":" | ","alterations":" TP53 expression • EPCAM expression","tags":["TP53 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • EPCAM expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2023-01-31"},{"id":"7645761f-f4b8-47f4-83e9-d65ee6dfcd9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05619562","created_at":"2022-11-17T15:57:39.394Z","updated_at":"2024-07-02T16:36:00.274Z","phase":"","brief_title":"Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients","source_id_and_acronym":"NCT05619562","lead_sponsor":"The Institute of Molecular and Translational Medicine, Czech Republic","biomarkers":" EGFR • MET • CEACAM5 • EPCAM","pipe":" | ","alterations":" EGFR expression • CEACAM5 expression • EPCAM expression","tags":["EGFR • MET • CEACAM5 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CEACAM5 expression • EPCAM expression"],"overall_status":"Completed","enrollment":" Enrollment 166","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2022-11-17"},{"id":"8e5f93bc-3ffd-4764-8091-f1ff7396a080","acronym":"","url":"https://clinicaltrials.gov/study/NCT05576519","created_at":"2022-10-12T13:56:52.092Z","updated_at":"2024-07-02T16:36:02.562Z","phase":"","brief_title":"Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma","source_id_and_acronym":"NCT05576519","lead_sponsor":"Sohag University","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2022-10-12"},{"id":"2a88a03e-1a74-4639-bea7-65d7f1196012","acronym":"","url":"https://clinicaltrials.gov/study/NCT05543330","created_at":"2022-09-16T15:56:39.623Z","updated_at":"2024-07-02T16:36:03.810Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","source_id_and_acronym":"NCT05543330","lead_sponsor":"Wuhan YZY Biopharma Co., Ltd.","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • M701"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-09-16"},{"id":"0a5b61b3-7667-454c-b61f-affb10bb9e77","acronym":"3CI Study","url":"https://clinicaltrials.gov/study/NCT04500548","created_at":"2021-01-18T21:33:32.102Z","updated_at":"2024-07-02T16:36:04.140Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","source_id_and_acronym":"NCT04500548 - 3CI Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression","tags":["TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 06/21/2022","primary_completion_date":" 06/21/2022","study_txt":" Completion: 06/21/2022","study_completion_date":" 06/21/2022","last_update_posted":"2022-09-12"},{"id":"0c72e324-a94b-4c79-b56d-8e07dee9bfbc","acronym":"CATUNIBLA","url":"https://clinicaltrials.gov/study/NCT04819399","created_at":"2021-03-29T12:52:24.159Z","updated_at":"2024-07-02T16:36:14.078Z","phase":"Phase 1","brief_title":"Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC","source_id_and_acronym":"NCT04819399 - CATUNIBLA","lead_sponsor":"Lindis Biotech GmbH","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Korjuny (catumaxomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-04-05"},{"id":"c3302dc6-ba26-4028-98fe-dbf5619a3fc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01713699","created_at":"2021-01-18T07:28:05.445Z","updated_at":"2024-07-02T16:36:35.780Z","phase":"","brief_title":"Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases","source_id_and_acronym":"NCT01713699","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 09/06/2016","primary_completion_date":" 09/06/2016","study_txt":" Completion: 09/19/2017","study_completion_date":" 09/19/2017","last_update_posted":"2021-01-22"},{"id":"34064796-0c71-458d-8d33-fdc531307128","acronym":"","url":"https://clinicaltrials.gov/study/NCT04151186","created_at":"2021-01-21T07:54:44.233Z","updated_at":"2024-07-02T16:36:53.966Z","phase":"","brief_title":"A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors","source_id_and_acronym":"NCT04151186","lead_sponsor":"suhaichuan","biomarkers":" EPCAM • IFIT3 • TM4SF1","pipe":" | ","alterations":" EPCAM expression • TM4SF1 expression","tags":["EPCAM • IFIT3 • TM4SF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression • TM4SF1 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 72","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 05/20/2021","primary_completion_date":" 05/20/2021","study_txt":" Completion: 11/20/2021","study_completion_date":" 11/20/2021","last_update_posted":"2019-11-05"},{"id":"596d8131-fa3c-41f7-8ed8-b5896e95b8e6","acronym":"EMR 62206-016","url":"https://clinicaltrials.gov/study/NCT00408967","created_at":"2021-01-21T07:52:13.240Z","updated_at":"2024-07-02T16:37:18.733Z","phase":"Phase 2","brief_title":"Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.","source_id_and_acronym":"NCT00408967 - EMR 62206-016","lead_sponsor":"EMD Serono","biomarkers":" EPCAM","pipe":" | ","alterations":" EPCAM expression","tags":["EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EPCAM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Celeuk (celmoleukin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/31/2006","start_date":" 12/31/2006","primary_txt":" Primary completion: 05/31/2008","primary_completion_date":" 05/31/2008","study_txt":" Completion: 05/31/2008","study_completion_date":" 05/31/2008","last_update_posted":"2017-08-18"}]